Skip to content
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Jezik
Vsa polja
Naslov
Avtor
Tema
Signatura
ISBN/ISSN
Oznaka
Išči
Napredno
Socrates phase II study result...
Citiraj
Pošljite SMS
Pošljite email
Natisni
Izvozi zadetek
Izvozi v RefWorks
Izvozi v EndNoteWeb
Izvozi v EndNote
Permanent link
Socrates phase II study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC).
Bibliografske podrobnosti
Main Authors:
Glynne-Jones, R
,
Sebag-Montefiore, D
,
Samuel, L
,
Falk, S
,
Maughan, T
,
McDonald, A
Format:
Conference item
Izdano:
2005
Zaloga
Opis
Podobne knjige/članki
Knjižničarski pogled
Podobne knjige/članki
Preliminary phase IISOCRATES study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (IRT) in patients (pts) with locally advanced rectal cancer (LARC).
od: Glynne-Jones, R, et al.
Izdano: (2004)
A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study.
od: Sebag-Montefiore, D, et al.
Izdano: (2005)
A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
od: Glynne-Jones, R, et al.
Izdano: (2007)
Capecitabine (X) and oxaliplatin (O) combination chemotherapy in patients (pts) with advanced gall bladder or biliary tract cancer: A phase II study
od: Evans, T, et al.
Izdano: (2006)
Preoperative chemoradiotherapy with capecitabine and triweekly oxaliplatin versus capecitabine monotherapy for locally advanced rectal cancer: a propensity-score matched study
od: Anchuan Li, et al.
Izdano: (2022-07-01)